Displaying drugs 1326 - 1350 of 1982 in total
TTP889
TTP889, an orally bioavailable selective inhibitor of the intrinsic coagulation pathway, is being developed as an anticoagulant for the treatment of thromboembolic disorders. TTP889 is the only known selective small molecule inhibitor of Factor IX, a key enzyme of the intrinsic pathway of the blood coagulation system. TTP889 has proven...
Investigational
PHE885
PHE885 is an investigational, autologous B-cell Maturation Antigen (BCMA)-directed chimeric antigen receptor (CAR)-T cell therapy.
Investigational
Anti-GD2 monoclonal antibody 3F8
Anti-GD2 monoclonal antibody 3F8 is under investigation in clinical trial NCT00089258 (Biological Therapy in Treating Patients With Neuroblastoma That Has Not Responded to Previous Treatment).
Investigational
DAS869
Experimental
BMS-830216
BMS-830216 is under investigation in clinical trial NCT00909766 (Safety, Pharmacokinetics and Pharmacodynamics Study to Evaluate BMS-830216 in Obese Subjects).
Investigational
BMS-833923
Investigational
Daphnetin
Daphnetin is under investigation in clinical trial NCT06329167 (Daphnetin Capsules for Lower Limb Lymphoedema Following Gynaecological Surgery).
Investigational
Devimistat
Devimistat (CPI-613) has been used in trials studying the treatment of Cancer, Lymphoma, Solid Tumors, Advanced Cancer, and Pancreatic Cancer, among others.
Investigational
Omburtamab I-131
Investigational
Granaticin B
Investigational
ZK-805623
Experimental
BI-836826
Investigational
AT845
Investigational
Icariin
Icariin has been investigated for the basic science of the Pharmacokinetic Profile of Icariin in Humans.
Investigational
Matched Iupac: … 5-hydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-en-1-yl)-7-{[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl …
H3B-8800
H3B-8800 is a novel spliceosome inhibitor developed by H3 Biomedicine . It offers the benefit of preferentially killing spliceosome-mutant cancer cells whereas other splicesome inhibitors, such as the pladienolide analogue E7107, show no such preferential targeting . H3B-8800 was granted orphan drug status by the FDA in August 2017 and...
Investigational
Chiniofon
Experimental
Matched Iupac: … sodium 8-hydroxy-7-iodoquinoline-5-sulfonic acid hydrogen carbonate …
Urolithin A
Urolithin A is a metabolite of ellagic acid. It has been demonstrated to stimulate mitophagy and improve muscle health in old animals and in preclinical models of aging.
Investigational
Dapoxetine
Dapoxetine is a selective serotonin reuptake inhibitor, for the treatment of premature ejaculation. In a phase II proof-of-concept study conducted by PPD, dapoxetine demonstrated a statistically significant increase in ejaculatory latency when compared to placebo. Alza submitted a NDA to the FDA for dapoxetine for the treatment of premature ejaculation...
Investigational
Matched Mixtures name: … TADA PLUS 30/20 MG FILM KAPLI TABLET ,8 ADET …
BMS-817399
BMS-817399 is under investigation in clinical trial NCT01404585 (Proof-of-Concept Study With BMS-817399 to Treat Moderate to Severe Rheumatoid Arthritis).
Investigational
Displaying drugs 1326 - 1350 of 1982 in total